一种新的皮肤下发酵胺配方,用于心力衰竭的门诊治疗
Katherine Sandquist1, James Nawarskas2, Mark E Garcia1
1From the University of New Mexico Hospital, Albuquerque, NM.
Cardiology in review
|April 8, 2024
概括
对于过多的液体负荷而言,腹腔利尿疗法通常需要去医院看病. 皮下注射的富罗塞米德 (Furoscix) 提供了潜在的家庭使用替代方案,改善了患者的便利性,并降低了心力衰竭管理的医疗保健成本.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亲体利尿疗法对于管理患者的液体过载和拥堵至关重要.
- 目前的管理方法往往需要住院或诊所访问,增加医疗负担.
研究的目的:
- 审查皮下注射富洛塞米德的药理学概况.
- 评估皮下注射富洛塞米德的使用,以治疗心力衰竭患者的血栓塞,特别是从急诊室出院时.
主要方法:
- 文献综述侧重于皮下注射富洛塞米德的药理动力学数据和临床效用.
- 分析涉及息治疗,门诊和急诊部出院的研究.
主要成果:
- 皮下注射的富罗塞米德 (Furoscix) 是一种新的家庭使用配方.
- 对患者和医疗保健系统来说,可能会大大节省成本.
- 新出现的证据支持其在急诊部排放设置中的使用.
结论:
- 皮下注射的罗塞米德为心力衰竭患者提供了一个有前途的替代方案,而不是传统的腹腔导尿疗法.
- 通过Furoscix进行家庭管理可以提高患者的便利性,并可能降低医疗保健支出.
- 进一步的研究支持其在管理慢性心力衰竭恶化中的不断扩大的作用.
相关概念视频
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577
Antihypertensive Drugs: Thiazide-Class Diuretics
620
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
620
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337


